These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 21736424)

  • 1. Enhancement of Gag-specific but reduction of Env- and Pol-specific CD8+ T cell responses by simian immunodeficiency virus nonstructural proteins in mice.
    Zhang Y; Sun C; Feng L; Xiao L; Chen L
    AIDS Res Hum Retroviruses; 2012 Apr; 28(4):374-83. PubMed ID: 21736424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys.
    Someya K; Xin KQ; Ami Y; Izumi Y; Mizuguchi H; Ohta S; Yamamoto N; Honda M; Okuda K
    Virology; 2007 Oct; 367(2):390-7. PubMed ID: 17628628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins.
    Leung NJ; Aldovini A; Young R; Jarvis MA; Smith JM; Meyer D; Anderson DE; Carlos MP; Gardner MB; Torres JV
    Virology; 2000 Mar; 268(1):94-103. PubMed ID: 10683331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic T lymphocyte response against multiple simian immunodeficiency virusA (SIV) proteins in SIV-infected macaques.
    Venet A; Bourgault I; Aubertin AM; Kiény MP; Levy JP
    J Immunol; 1992 May; 148(9):2899-908. PubMed ID: 1349322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression.
    Engram JC; Dunham RM; Makedonas G; Vanderford TH; Sumpter B; Klatt NR; Ratcliffe SJ; Garg S; Paiardini M; McQuoid M; Altman JD; Staprans SI; Betts MR; Garber DA; Feinberg MB; Silvestri G
    J Immunol; 2009 Jul; 183(1):706-17. PubMed ID: 19542473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease.
    McKenna PM; Koser ML; Carlson KR; Montefiori DC; Letvin NL; Papaneri AB; Pomerantz RJ; Dietzschold B; Silvera P; McGettigan JP; Schnell MJ
    J Infect Dis; 2007 Apr; 195(7):980-8. PubMed ID: 17330788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
    Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
    J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.
    Suh YS; Park KS; Sauermann U; Franz M; Norley S; Wilfingseder D; Stoiber H; Fagrouch Z; Heeney J; Hunsmann G; Stahl-Hennig C; Sung YC
    Vaccine; 2006 Mar; 24(11):1811-20. PubMed ID: 16274888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substantial envelope-specific CD8 T-cell immunity fails to control SIV disease.
    Peut V; Kent SJ
    Virology; 2009 Feb; 384(1):21-7. PubMed ID: 19091370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques.
    Boyer JD; Robinson TM; Kutzler MA; Parkinson R; Calarota SA; Sidhu MK; Muthumani K; Lewis M; Pavlakis G; Felber B; Weiner D
    J Med Primatol; 2005 Oct; 34(5-6):262-70. PubMed ID: 16128921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenovirus 5- and 35-based immunotherapy enhances the strength but not breadth or quality of immunity during chronic SIV infection.
    Soloff AC; Liu X; Gao W; Day RD; Gambotto A; Barratt-Boyes SM
    Eur J Immunol; 2009 Sep; 39(9):2437-49. PubMed ID: 19670380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No difference in Gag and Env immune-response profiles between vaccinated and non-vaccinated rhesus macaques that control immunodeficiency virus replication.
    Nieuwenhuis I; Beenhakker N; Bogers WM; Otting N; Bontrop RE; Dubois P; Mooij P; Heeney JL; Koopman G
    J Gen Virol; 2010 Dec; 91(Pt 12):2974-84. PubMed ID: 20826621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
    Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
    Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of balance and breadth in the immune response is beneficial for the control of SIVmac239 replication in rhesus monkeys.
    Sun C; Zhang L; Zhang M; Liu Y; Zhong M; Ma X; Chen L
    J Infect; 2010 May; 60(5):371-81. PubMed ID: 20227437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of retroviral vectors for the analysis of SIV/HIV-specific CD8 T cell responses.
    Negri DR; Buffa V; Leone P; Bona R; Borghi M; Carlini F; De Angelis F; Indraccolo S; Ensoli B; Cara A
    J Immunol Methods; 2004 Aug; 291(1-2):153-63. PubMed ID: 15345313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing cellular immunity against HIV-1 Gag and preventing suppression by HIV-1 gp120.
    van Montfort T; Sanders RW
    Expert Rev Vaccines; 2012 Oct; 11(10):1175-7. PubMed ID: 23176650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigenic competition in CD4
    Kallas EG; Grunenberg NA; Yu C; Manso B; Pantaleo G; Casapia M; Baden LR; Valencia J; Sobieszczyk M; Van Tieu H; Allen M; Hural J; Graham BS; Kublin J; Gilbert PB; Corey L; Goepfert PA; McElrath MJ; Johnson RP; Huang Y; Frahm N
    Sci Transl Med; 2019 Nov; 11(519):. PubMed ID: 31748227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Env- and Gag-specific T cell responses in relation to programmed death-1 receptor and CD4 T cell loss rates in human immunodeficiency virus-1 infection.
    Pettersen FO; Taskén K; Kvale D
    Clin Exp Immunol; 2010 Aug; 161(2):315-23. PubMed ID: 20491784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of long term protection with the inclusion of HIV pol to a DNA vaccine encoding gag.
    Garrod TJ; Gargett T; Yu W; Major L; Burrell CJ; Wesselingh S; Suhrbier A; Grubor-Bauk B; Gowans EJ
    Virus Res; 2014 Nov; 192():25-33. PubMed ID: 25152448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.